{"id":"tedizolid-bay119-2631","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2105669","moleculeType":"Small molecule","molecularWeight":"450.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tedizolid works by binding to the 50S ribosomal subunit of bacteria, preventing the formation of the 70S initiation complex and thereby inhibiting protein synthesis. This leads to the death of the bacterial cell. Tedizolid has a broad spectrum of activity against Gram-positive bacteria, including MRSA.","oneSentence":"Tedizolid is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:43.291Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"}]},"trialDetails":[{"nctId":"NCT02991131","phase":"","title":"Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-12-17","conditions":"Skin Disease, Infectious","enrollment":108},{"nctId":"NCT01967225","phase":"PHASE3","title":"Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-11-23","conditions":"Skin Diseases, Infectious","enrollment":125},{"nctId":"NCT02066402","phase":"PHASE3","title":"Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-04","conditions":"Bacterial Infections","enrollment":598}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tedizolid (BAY119-2631)","genericName":"Tedizolid (BAY119-2631)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tedizolid is an oxazolidinone antibiotic that inhibits protein synthesis in bacteria. Used for Acute bacterial skin and skin structure infections (ABSSSI).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}